Litcius/Paper detail

Advances in deubiquitinating enzymes in lung adenocarcinoma

Xijia Zhou, Rui Li, Xiao Liu, Yi-Qing Qu

2021Journal of Cancer19 citationsDOIOpen Access PDF

Abstract

The process of ubiquitination and deubiquitination is widely present in the human body's protein reactions and plays versatile roles in multiple diseases. Deubiquitinating enzymes (DUBs) are significant regulators of this process, which cleave the ubiquitin (Ub) moiety from various substrates and maintain protein stability. Lung adenocarcinoma (LUAD) is the most common type of non-small cell lung cancer (NSCLC) and remains refractory to treatment. To elucidate the mechanism of LUAD and advance new therapeutic targets, we review the latest research progress on DUBs in LUAD. We summarize the biological capabilities of these DUBs and further highlight those DUBs that may serve as anticancer target candidates for precision treatment. We also discuss deubiquitinase inhibitors, which are expected to play a role in targeted LUAD therapy.

Topics & Concepts

Deubiquitinating enzymeUbiquitinCancer researchAdenocarcinomaEnzymeComputational biologyBiologyChemistryCancerBiochemistryGeneGeneticsUbiquitin and proteasome pathwaysGlycosylation and Glycoproteins ResearchCancer, Hypoxia, and Metabolism
Advances in deubiquitinating enzymes in lung adenocarcinoma | Litcius